Pivotal clinical study by Trophos with olesoxime in ALS did not reach statistical significance on the primary endpoint

Via Scoop.it – ALS Lou Gehrig’s Disease
ALLSCHWIL, SWITZERLAND – 13 December 2011 – Actelion Ltd announced today, following the communication of the pivotal Phase III results in patients suffering from Amyotrophic Lateral Sclerosis (ALS) by privately-held Trophos S.A., that it has decided not to exercise the option to acquire the company.
Via www.marketwatch.com